COMMUNIQUÉS West-GlobeNewswire

BioSig‘s Subsidiary NeuroClear Technologies, Inc. Raises $3.7 million
05/09/2019
The Company to develop solutions to advance bioelectronic medicine Westport, CT, Sept. 05, 2019 (GLOBE NEWSWIRE) -- BioSig Technologies, Inc. (NASDAQ: BSGM), a medical device company developing a proprietary biomedical [...]
Auxly Announces Receipt of Cannabis Research Licence to KGK Science
05/09/2019
VANCOUVER, British Columbia, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Auxly Cannabis Group Inc. (TSX.V - XLY) (“ Auxly ” or the “ Company ”) today announced that its wholly-owned subsidiary, KGK Science Inc. (“ KGK ”), has [...]
European Research Initiative Adopts PacBio Sequel II System to Solve Rare Diseases
05/09/2019
SOLVE-RD program will sequence more than 500 human genomes with SMRT Sequencing MENLO PARK, Calif., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high- [...]
KemPharm to Present at the 21st Annual Global Investment Conference, Sponsored By H.C. Wainwright & Co.
05/09/2019
CELEBRATION, Fla., Sept. 05, 2019 (GLOBE NEWSWIRE) -- KemPharm, Inc. (Nasdaq:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that its president [...]
Wave Life Sciences Expands Board of Directors with Three New Appointments
05/09/2019
New independent directors bring deep expertise in drug development, commercial operations and government affairs CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical- [...]
Scholar Rock Announces Appointment of George Nomikos, M.D., Ph.D., as Vice President, Head of Medical Research, Muscle Franchise
05/09/2019
Highly experienced physician-scientist and drug developer to lead SRK-015 latent myostatin program CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Scholar Rock Holding Corporation (NASDAQ: SRRK), a clinical-stage [...]
Solid Biosciences Announces Publication Highlighting the Important Role of the nNOS Domain in Microdystrophin Function and its Potential Utility in DMD Gene Therapy in the Journal Neuromuscular Disorders
05/09/2019
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) today announced the publication of a review article in the journal Neuromuscular Disorders ¹ that summarizes the evidence [...]
Stemline Therapeutics to Present at the H.C. Wainwright 21st Annual Global Investment Conference
05/09/2019
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Stemline Therapeutics, Inc. (Nasdaq: STML), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel oncology therapeutics, [...]
New Caregiver-Reported Data Further Validate the Use of the Aberrant Behavior Checklist Community: FXS Specific (ABC-CFXS) Subscales to Assess Core Behavioral Symptoms of Fragile X Syndrome (FXS)
05/09/2019
- Ninety Percent of Interviewed Caregivers Reported Social Avoidant, Irritability, and Socially Lethargic Behaviors in their Children with FXS - - New Data Presented Today at the Society for the Study of Behavioural [...]
Autism Spectrum Disorder, Fragile X Syndrome, and 22q11.2 Deletion Syndrome Share a Constellation of Sociobehavioral Symptoms
05/09/2019
- Preliminary Evidence Shows that CBD May Prove to be Effective in Managing the Spectrum of Behavioral Symptoms Associated with these Conditions – - New Data Presented Today at the Society for the Study of Behavioural [...]
Summit Presented In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotics at ASM/ESCMID Conference
05/09/2019
Summit Therapeutics plc (‘Summit’ or the ‘Company’) Summit Presents In Vivo Proof of Concept Data for Targeted Enterobacteriaceae Antibiotic at ASM/ESCMID Conference New Mechanism Antibiotic has Potential to Overcome [...]
Zafgen to Explore Strategic Alternatives
05/09/2019
Preliminary results from in vivo animal study not expected to warrant near-term resolution of clinical hold for ZGN-1061 BOSTON, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage [...]
Unum Therapeutics to Present at Upcoming Industry Conferences in September
05/09/2019
CAMBRIDGE, Mass., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Unum Therapeutics Inc. (NASDAQ: UMRX), a clinical-stage biopharmaceutical company focused on developing curative cell therapies for cancer, today announced its [...]
Microbix Quality Products Attain European Registration
05/09/2019
Four IVD Controls to Support Performance of Human Papilloma Virus (HPV) Tests MISSISSAUGA, Ontario, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Microbix Biosystems Inc. (TSX: MBX, Microbix®), an innovator of biological products [...]
Trillium Therapeutics To Present At Investor Conference
05/09/2019
TORONTO, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (NASDAQ/TSX: TRIL), a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, announced today that the [...]
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019
05/09/2019
NEW YORK, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of [...]
Axsome Therapeutics Presents Positive AXS-07 Phase 1 Trial Results at the 19th Congress of the International Headache Society
05/09/2019
Dual mechanisms, rapid absorption and long half-life support therapeutic potential of AXS-07 in migraine AXS-07 MOMENTUM Phase 3 trial ongoing in migraine patients with history of inadequate response to prior acute [...]
Nabriva Therapeutics to Present Data at ASM/ESCMID Conference Demonstrating Utility of Xenleta™ (lefamulin) for Patients with Community-Acquired Bacterial Pneumonia (CABP)
05/09/2019
DUBLIN, Ireland, Sept. 05, 2019 (GLOBE NEWSWIRE) -- Nabriva Therapeutics plc (NASDAQ: NBRV), a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat [...]
Novan and Aspire Capital Enter into a Common Stock Purchase Agreement for up to $25 Million
05/09/2019
MORRISVILLE, N.C., Sept. 05, 2019 (GLOBE NEWSWIRE) -- Novan, Inc. ("the Company" or "Novan") (Nasdaq:NOVN) today announced that the Company has entered into a Common Stock Purchase Agreement (the “Agreement”) of up to $ [...]

Pages